Given that inhibition of wild-type EGFR in normal tissues is associated with dose-limiting toxicities, substantial clinical benefit in NSCLC has been associated with TKIs that inhibit specific, activated variants of EGFR more potently than they inhibit wild-type EGFR [4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.